Sanofi (SNYNF) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The Phase 2b study titled “A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Moderate-to-severe Asthma” tests Sanofi’s (SNYNF) new asthma drug in adults with hard-to-control disease. The goal is to find the best dose and schedule while checking safety, which could shape Sanofi’s next move in respiratory care.
The trial evaluates lunsekimig, a subcutaneous injection designed as an add-on therapy for adults with moderate-to-severe asthma. It is compared against a placebo injection, aiming to reduce asthma symptoms and attacks when standard treatments are not enough.
The study uses a randomized design, meaning participants are assigned by chance to different doses of lunsekimig or placebo. It is triple-blind and placebo-controlled, so participants, doctors, and study staff do not know who gets which treatment, and the main purpose is to treat asthma and see which dose works best with acceptable side effects.
The trial started after initial submission on Oct. 20, 2023, marking the formal launch of Sanofi’s Phase 2b program in this indication. The study is now listed as completed, and the latest update on Mar. 16, 2026, signals that new data or analyses were recently captured, with full study completion expected to guide later-stage plans.
For investors, this update suggests Sanofi is advancing a potential follow-on asthma asset that could complement or, longer term, diversify beyond its flagship biologics. Competitors like AstraZeneca and GSK also vie for share in severe asthma, so positive dose-ranging data may lift sentiment on Sanofi’s pipeline strength and support the stock’s valuation versus peers.
The study has been completed and recently updated, and further details are available on the ClinicalTrials portal.
To learn more about SNYNF’s potential, visit the Sanofi drug pipeline page.